Peter Saltonstall, president of the National Organization of Rare Disorders, speaks at a rally Tuesday in support of tax credits for companies that develop drugs for rare diseases.
Sarah Jane Tribble/KHN
Speaker of the House Paul Ryan, center, and other lawmakers have a plan to overhaul the tax code that includes a provision that would repeal a tax credit for makers of drugs for rare diseases.
Alex Wong/Getty Images
A multi-million dollar effort to produce a test to guide treatment for a potentially lethal skin cancer recently fell apart after the scientific investigator discovered that the commercial antibodies he was using were unreliable.
Cultura RM Exclusive/Peter Mulle/Getty Images
In 2015, the Sandoz unit of drugmaker Novartis won Food and Drug Administration approval of a drug called Zarxio, which is similar to Amgen's Neupogen, a medicine that boosts the production of white blood cells.
Sebastien Bozon/AFP/Getty Images
Multiple sclerosis pill Tecfidera is on the top 10 list of most costly specialty drugs, as measured by overall spending, for California's health benefit system for public workers and retirees.
This genetically modified yeast can convert sugar into powerful opioid drugs. Scientists working with the modified yeast strains are required to register them with the Drug Enforcement Administration and keep the yeast under lock and key.
Courtesy of Christina Smolke/Stanford University